<DOC>
	<DOCNO>NCT00682032</DOCNO>
	<brief_summary>The purpose study determine beta-glucan affect immune system subject non-small cell lung cancer .</brief_summary>
	<brief_title>The Effect Beta-glucan Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Beta-glucan ( Imucell WGP ) over-the-counter dietary supplement enhance body 's immune system . Imucell WGP extract food-grade baker 's yeast , permit use food U.S. Food Drug Administration ( FDA ) . Studies animal show Imucell WGP help trigger white blood cell destroy cancer cell . Other animal study combine Imucell WGP anti-cancer medication show great tumor regression tumor-free survival .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>AIM 2 : suspect definitive diagnosis nonsmall cell lung cancer ( NSCLC ) treatment naive treatment within 6 month prior enrollment able swallow pill Eastern Cooperative Oncology Group ( ECOG ) performance status 0 3 absolute neutrophil count ( ANC ) least 1500/microl able understand willing sign write informed consent document history hypersensitivity reaction attribute betaglucan currently receive continuous corticosteroid ongoing immunosuppressive therapy presence uncontrolled intercurrent illness include limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement AIM 3 : resectable nonsmall cell lung cancer ( NSCLC ) , determine thoracic surgeon treatment naive able swallow pill Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 must operative candidate absolute neutrophil count ( ANC ) least 1500/microl able understand willing sign write informed consent document history hypersensitivity reaction attribute betaglucan currently receive continuous corticosteroid ongoing immunosuppressive therapy presence uncontrolled intercurrent illness include limited : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NSCLC</keyword>
</DOC>